- Case details
- Status—ActionProcedural applicationCategoryFile-access requests (R. 262.1(b))
- Parties
- Respondents
- Merz Therapeutics GmbHOperating co.
- Merz Pharmaceuticals LLCOperating co.
- Merz Pharma FranceOperating co.
- Viatris SantéOperating co.
Representatives- Laëtitia Bénard-A&O Shearman
- Marc Lauzeral-Schertenleib
- Division
- Paris LD
- Judges
- —
- Technology
- ChemistryPharmaceuticals
- Language
- —
- First decided
- Feb 19, 2026
- EPO Opposition
- Actavis Group PTC ehfAdmissible2013-12-05
- Synthon B.V.Admissible2013-12-06
- neuraxpharm Arzneimittel GmbHAdmissible2013-12-06
| Median days to first decision | |
|---|---|
| All UPC | 124 |
| Paris LD | Locked |
At the UPC: Gowling WLG (0 cases)·Merz Therapeutics GmbH (6 cases)
6 other defendants litigating the same or a related patent
UPC CFI 3290/2026·UPC CFI 3259/2026·UPC CFI 1901/2026·UPC CoA 917/2025·UPC CoA 906/2025 and 1 more
- 2026-02-19Application RoP262.1 (b)Public
Summary: The Paris Local Division (judge-rapporteur) granted Gowling WLG's application under R. 262.1(b) RoP for access to specific documents in the case file of UPC_CFI_697/2025 (Merz v Viatris provisional measures proceedings). Access was granted to certain procedural pleadings and exhibits concerning specific procedural issues (page limits in objections, extension of time in provisional measures proceedings, and the 'unreasonable delay' criterion under R. 211.4 RoP), but denied for other documents not relevant to the stated purpose. The application was found admissible as Gowling demonstrated a legitimate interest in understanding the court's handling of provisional measures.
Show the legal issues (4)
- Public access to case file (R. 262.1(b) RoP)
- Legitimate interest of law firm in accessing case file
- Scope of access granted to third parties
- Transparency of UPC proceedings
- Order%20public%20access%20MERZ%2019%20Feb%2026%20signed%20CL.pdf2026-02-19EN